Outlook Therapeutics (OTLK) Depreciation & Amortization (CF) (2015 - 2026)
Outlook Therapeutics (OTLK) posted quarterly Depreciation & Amortization (CF) of $30417.0 for Q1 2026, up 4.52% year-over-year from $29102.0 in Q1 2025, and up 1.14% quarter-over-quarter from $30074.0 in Q4 2025.
Outlook Therapeutics (OTLK) Depreciation & Amortization (CF) (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Depreciation & Amortization (CF) for 12 consecutive years, with $30417.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 4.52% year-over-year to $30417.0; the TTM figure through Mar 2026 stood at $119640.0 (up 3.7% YoY), while the FY2025 annual figure was $117052.0, up 2.8% from the prior year.
- Depreciation & Amortization (CF) grew to $30417.0 in Q1 2026 per OTLK's latest filing, from $30074.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $51470.0 in Q3 2022 and bottomed at $10778.0 in Q4 2022.
- Historically, Depreciation & Amortization (CF) has averaged $28789.2 across 5 years, with a median of $28801.0 in 2024.
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) sank 78.81% — and 2023, when it jumped 161.6%.
- Outlook Therapeutics' Depreciation & Amortization (CF) stood at $10778.0 in 2022, then jumped by 161.6% to $28195.0 in 2023, then increased by 2.15% to $28801.0 in 2024, then increased by 4.42% to $30074.0 in 2025, then advanced by 1.14% to $30417.0 in 2026.
- Business Quant data shows OTLK's Depreciation & Amortization (CF) at $30417.0 in Q1 2026, $30074.0 in Q4 2025, and $29737.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Outlook Therapeutics | 88.50 Mn | 77.26 Mn | -8,265.00 | 13,791.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30,417.00 |
| Mar 31, 2026 | 30,417.00 |
| Dec 31, 2025 | 30,074.00 |
| Dec 31, 2025 | 30,074.00 |
| Sep 30, 2025 | 29,737.00 |
| Sep 30, 2025 | 29,737.00 |
| Jun 30, 2025 | 29,412.00 |
| Jun 30, 2025 | 29,412.00 |
| Mar 31, 2025 | 29,102.00 |
| Mar 31, 2025 | 29,102.00 |
| Dec 31, 2024 | 28,801.00 |
| Dec 31, 2024 | 28,801.00 |
| Sep 30, 2024 | 28,797.00 |
| Sep 30, 2024 | 28,797.00 |
| Jun 30, 2024 | 28,672.00 |
| Jun 30, 2024 | 28,672.00 |
| Mar 31, 2024 | 28,195.00 |
| Mar 31, 2024 | 28,195.00 |
| Dec 31, 2023 | 28,195.00 |
| Dec 31, 2023 | 28,195.00 |